Cencora, Inc.
CORHealthcareNASDAQMedical Distribution
Scan Results
Daily timeframeCencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. At a $63.16B market cap, Cencora, Inc. ranks as a large-cap company within healthcare.
Market Cap
$63.16B
Beta
0.58
P/E (TTM)
24.57
P/E (Fwd)
16.75
EPS (TTM)
$13.47
EPS (Fwd)
$19.76
ROE
96.9%
ROA
3.6%
Cash
$2.82B
Total Debt
$14.46B
Free CF
$2.04B
52W Change
-1.5%
Annual Financials
Cash vs Debt
Where COR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, COR finished 11.70% above its 150-day moving average ($304.39) and 7.40% above its 200-day moving average ($316.58). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is COR overbought or oversold?
At the October 20, 2026 close, COR's RSI(14) was 81.5, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, COR has $2.82B in cash with $14.46B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $2.04B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 96.9% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.6% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $238.59B (2022) to $321.33B (2025), reflecting a 35% increase over the period.
COR's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Cencora, Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Cencora, Inc. and its sector.